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Medication safetyDue to the patient's critical condition and continuous monitoring on the ICU, not all pDDIs are clinically relevant.
Clinical decision support systems (CDSSs) warning for irrelevant pDDIs could result in alert fatigue and
overlooking important signals. Therefore, our aim was to describe the frequency of clinically relevant pDDIsPurpose: Potential drug-drug interactions (pDDIs) may harm patients admitted to the Intensive Care Unit (ICU).
(crpDDIs) to enable tailoring of CDSSs to the ICU setting.
Materials & methods: In this multicenter retrospective observational study, we used medication administration
data to identify pDDIs in ICU admissions from 13 ICUs. Clinical relevance was based on a Delphi study in which
intensivists and hospital pharmacists assessed the clinical relevance of pDDIs for the ICU setting.
Results: The mean number of pDDIs per 1000 medication administrations was 70.1, dropping to 31.0 when con-
sidering only crpDDIs. Of 103,871 ICU patients, 38% was exposed to a crpDDI. The most frequently occurring
crpDDIs involve QT-prolonging agents, digoxin, or NSAIDs.
Conclusions: Considering clinical relevance of pDDIs in the ICU setting is important, as only half of the detected
pDDIs were crpDDIs. Therefore, tailoring CDSSs to the ICU may reduce alert fatigue and improve medication
safety in ICU patients.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
A recent systematic review estimated that 58% of the Intensive Care
Unit (ICU) patients are exposed to a potential drug-drug interaction
(pDDI) [1]. This is twice asmuch as in generalwards [2]. A pDDI is defined
as two drugs administered concomitantly, potentially interacting through
pharmacokinetic or pharmacodynamic mechanisms [2]. pDDIs may lead
to actual DDIs and result in Adverse Drug Events (ADE), causing higher
mortality and morbidity, prolonged length of stay (LOS), and increased
hospital costs [3]. On average, 30 different medications are administered
to ICU patients during ICU stay and each intravenous medication admin-
istered increases the ADE risk by 3% [1,4]. Besides polypharmacy, ICU pa-
tients often suffer from impaired kidney and hepatic function, exposing
them to increased risks of drug toxicity [5].
The condition of ICU patients may require administration of poten-
tially interacting medications. Furthermore, ICU patients are continu-
ously monitored, enabling timely detection and risk management of
potential adverse effects. Therefore, ICU patients may encounter a
high number of pDDIs, but not all pDDIs are clinically relevant. As
Fitzmaurice et al. stated [1], pDDI frequency is not always indicative of
clinical relevance, and more research is needed to understand the clin-
ical relevance of pDDIs in the ICU.
Yet, most studies assessing clinical relevance of pDDIs in the ICU
based their clinical relevance definition on severity categories from in-
teraction databases [1]. Since interaction databases are not tailored to
the ICU setting, their severity categories are less appropriate for the
ICU. Additionally, the majority were single-center studies with rela-
tively small samples, limiting generalizability [1].
To address these limitations, we previously conducted a Delphi study
with an expert panel of 27 hospital pharmacists and intensivists from 14
different ICUs to assess the clinical relevance of 148 pDDI types for ICUpa-
tients, of which 86 pDDI types were considered clinically relevant [6].
The aim of this large multicenter study was to describe the fre-
quency and type of clinically relevant pDDIs (crpDDIs) in the ICU. This
will improve our understanding of the extent and risks of crpDDI expo-
sure in ICU patients, and may inform the development of appropriate
clinical decision support systems (CDSS).
2. Materials and methods
2.1. Study design
In this multicenter retrospective observational study, we determined
the frequency and type of crpDDIs on the ICU, based on routinely-
collected medication administration data. This study is reported accord-
ing to the RECORD-PE statement [7] (Supplementary file 1).1252.2. ICU and patient inclusion
All fifteen Dutch ICUs using the commercial patient data manage-
ment system (PDMS)Metavision©at the timeof the studywere invited.
Thirteen ICUs agreed to participate, two declined because theyweremi-
grating to another PDMS. Adult patients (18 years and older) admitted
to the ICU within the study period with at least two administered med-
ications were included. No further exclusion criteria were used. All ad-
mission days were included.
The study period lasted from January 2010 until July 2017 (7.5 years).
Four ICUs implemented Metavision© after January 2010 or migrated to
another PDMS before July 2017 reducing their study period by one to
four years. During the study period, seven ICUs implemented a CDSS
warning prescribers through pDDI alerts during order entry. The other
six ICUs did not have a CDSS in place. The seven ICUs that implemented
a CDSS during the study period did not show a qualitative change in (cr)
pDDIs after CDSS implementation.
At the thirteen study sites, hospital pharmacists provided central-
ized clinical pharmacy services on prescribing, consisting of daily on-
call availability for medication-related problems. Hospital pharmacists
had no access to the CDSS alerts.
2.3. Data sources
All medication administration data were extracted from the PDMS
using validated queries. Medication administration data included
name, dose, administration route, and start and stop date and time per
administration of eachmedication during admission. If the time interval
between administrations of the same medication did not exceed 24 h,
the separate administrations were merged into one medication admin-
istration record. The resulting recordwas given the start time of thefirst
administration and the stop time of the last administration.
To characterize the study population, themedication administration
datasetwas enriched by linking it with the National Intensive Care Eval-
uation (NICE) quality registry in which all Dutch ICUs participate [8].
The following characteristics were included: ICU LOS, admission type,
admission diagnosis, presence of chronic conditions, ICUmortality, hos-
pital mortality, and expected mortality. ICU admissions that could not
be linked with the NICE database were excluded.
2.4. pDDI detection
To detect pDDIs in the medication administration data, we used the
G-standard drug database [9]. The G-standard is an evidence-based pro-
fessional drug database, used in electronic prescribing systems in Dutch
hospitals [2]. Medications are represented by a generic product code
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example, the pDDI type NSAIDs + corticosteroids is represented by
14,190 GPK combinations of medication subtypes, such as ibuprofen
+ dexamethasone. The G-standard provides a summary of mecha-
nism(s) and potential risk(s) of each pDDI, and recommendations to
handle the pDDI [9].We used the February 2017G-standard version, in-
cluding 557 pDDIs (see Supplementary file 2). To detect pDDIs using
the G-standard, we mapped all medication names in the medication
administration data to GPK codes.
For this study, we developed a computerized algorithm to detect
pDDIs, incorporating information from the G-standard. The algorithm
defines a pDDI as the administration of two potentially interactingmed-
ications within a time interval of 24 h maximum. For example, if medi-
cation A interacts with medication B, and the time interval between the
stop time of A and the start time of B is 24 h or less, it was considered a
pDDI. The pDDI start was defined as the start time of A and the pDDI
stop as the stop time of B. The pDDI duration is the time difference be-
tween the pDDI start and the pDDI stop.
Per pDDI type, each combination of interacting medications was
counted separately. For example, if a patient received NSAIDs and
two corticosteroids both interacting with NSAIDs, these interactions
were counted separately. If a pDDI occurred more than once, all oc-
currences were counted if the time interval between the occurrences
was more than 24 h. Two developers validated the algorithm through
unit testing [10].
Clinical relevance of a pDDI in the ICUwas based on a previous study
[6]. Supplementary file 3 lists the 86 crpDDI types.
2.5. Outcome measures
The primary outcome was the number of crpDDIs per 1000 medica-
tion administrations. This contrasts some previous studies using patient
days to express pDDI rate [1]. Expressing a crpDDI rate per 1000 admin-
istrations seemsmore appropriate since not all admission days hold the
same risk for crpDDIs. Patients with a longer LOS are more at risk in the
first admission days. To enable comparison to other studies, we also re-
port secondary outcome measures used in other studies [1], including
the number of crpDDIs per ICU admission, the proportion of ICU admis-
sions with at least one crpDDI, and the distribution of crpDDIs over
admission days.
To improve our understanding of potential risks of crpDDIs, we cat-
egorized crpDDI types according to its potential clinical consequences
and monitoring strategy following the example of Uijtendaal et al. [2].
Furthermore, the fifteen most frequently occurring crpDDI types will
be presented.
Additionally, crpDDI duration and pDDIs at ICU discharge will be de-
scribed. crpDDI duration is important since pharmacokinetic/pharma-
codynamic mechanisms are often time-dependent, e.g. for crpDDIs
with an underlying livermetabolism inductionmechanism, it takes sev-
eral days to produce an induction effect on the enzymes involved [11].
Knowing which pDDIs are present at ICU discharge could help
intensivists guide transfers to non-ICU wards with less frequent moni-
toring. This estimate included all pDDIs, independent of clinical
relevance.
2.6. Statistical analysis
Count and continuous variables are characterized by mean with
standard deviation, or median with interquartile range, depending on
their distribution.
Aside from the crpDDI set, all primary and secondary outcomeswere
calculated on the complete set of pDDIs. Furthermore, a subgroup anal-
ysis of crpDDIswas performed for patients with aminimum LOS of 24 h,
enabling comparison to other studies.126All data analyses and development of the detection algorithm were
performed in the R statistical environment (3.5.3) [12].3. Results
All 13 ICUsweremixedmedical-surgical closed format ICUs situated
in academic hospitals (n = 2), teaching hospitals (n = 7) and general
hospitals (n = 4) in the Netherlands. Together they represent 278
beds (mean: 21.4; SD: 13.4). The ICUs were geographically distributed
over the Netherlands. Fig. 1 shows the inclusion and data linkage pro-
cess. The resulting study population included 103,871 ICU admissions
corresponding to 2,282,974 administratedmedications. Table 1 displays
the patient characteristics.Themedian LOS was 1.03 days (IQR: 2.2; Q1:
0.8; Q3:3.0), totaling 364,855 ICU days. The median age was 66 (IQR:
19; Q1: 55; Q3: 74) and 61.4% were male. Most admissions were medi-
cal (42.2%) or elective surgery (44.2%), and 47.1% of the admissions had
a cardiovascular admission diagnosis.3.1. pDDI frequency
In 103,871 ICU admissions, 228,489 pDDIs were detected, corre-
sponding to 270 of 557 (48.5%) pDDI types. The mean number of
pDDIs per 1000 medication administrations was 70.1 (SD: 90.5) and
the mean number of pDDIs per admission was 2.2 (SD: 4.1). Of the
103,871 admissions, 56,561 (54.5%) had at least one pDDI.3.2. crpDDI frequency
Of the 228,489 detected pDDIs, 226,740 (99.2%) correspond to pDDI
types that were assessed for clinical relevance in the previous Delphi
study. Of those 226,740 pDDIs, 107,908 were crpDDIs (47.2% of all
pDDIs), corresponding to 85 crpDDI types, while 112,086 (49.0% of all
pDDIs) were not clinically relevant, corresponding to 53 pDDI types.
The remaining 6746 pDDIs (3.0% of all detected pDDIs), corresponding
to 9 pDDI types, were assessed but agreement regarding the clinical rel-
evance was not reached in the Delphi study. The mean number of
crpDDIs per 1000 medication administrations was 31.0 (SD: 53.7), and
the mean number of crpDDIs per admission was 1.0 (SD: 2.3). Of the
103,871 admissions, 39,661 (38.2%) had at least one crpDDI. Fig. 2a dis-
plays the number and percentage of admissions with 0 to 7 or more
crpDDIs.
Table 2 shows the 15 most frequently occurring crpDDIs types.
crpDDIs that might potentially lead to cardiac arrhythmias were most
frequent, including interactionswith QT-prolonging agents and interac-
tions with digoxin. These accounted for 80,631 (74.7%) of the detected
crpDDIs. Another frequent type was NSAIDs interactions, potentially
resulting in gastrointestinal bleeding (18.6%). Supplementary file 4
shows the top 15 of all pDDI types.
Supplementary file 5 summarizes the post-hoc analysis of patients
with a minimum LOS of 24 h. This subgroup had a higher frequency of
crpDDIs compared to thewhole group. Subgrouppatientswere on aver-
age exposed to 1.7 crpDDIs compared to 1.0, and 53.8%was exposed to a
crpDDI, compared to 38.2%.3.3. crpDDI timing
Fig. 2b shows the number of crpDDIs per admission day for day 1 to
day 15. crpDDIs mostly occurred on the first day while the following
days the risk decreased gradually. To obtain these results, the number
of crpDDIs on an admission day was divided by the number of admis-
sions on that day, correcting for differences in LOS. Supplementary file
4 shows the number of all pDDIs per admission day.
Fig. 1. Overview of data inclusion and linkage process.
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Most crpDDIs increased the potential risk of side effects (96.6%)
(Table 3). Within this category, potential risk of cardiac arrhythmias oc-
curredmost often (75.9%), followed by risk of bleeding (18.7%) and riskTable 1
Patient characteristics of included admissions (n = 103,871).
Characteristics n (%)
Age
median (Q1– Q3) 66 (55–74)
Gender (male) 63,726 (61.4%)
APACHE IV predicted mortalitya
median (Q1– Q3) 15 (11−21)
ICU mortality 8784 (8.5%)
Hospital mortality 12,955 (12.5%)
ICU Length of stay
median (Q1-Q3) 1.0 (0.8–3.0)
Admission type
Medical 43,788 (42.2%)
Emergency surgical 13,299 (12.8%)
Elective surgical 45,895 (44.2%)
Admission type missing 889 (0.8%)
Chronic conditions
Chronic kidney failure 5222 (5.0%)
COPD 12,966 (12.5%)
Respiratory failure 3867 (3.7%)
Cardiovascular disease 5752 (5.5%)
Cirrhosis 1132 (1.1%)
Hematological malignancy 1673 (1.6%)
AIDS 205 (0.2%)
Immunodeficiency 9982 (9.6%)











Admission diagnosis missing 1221 (1.2%)
a Calculated within the first 24 h of ICU admission using the APACHE IV model
APACHE = Acute Physiology And Chronic Health Evaluation, ICU = Intensive Care
Unit, COPD = Chronic Obstructive Pulmonary Disease, AIDS = Acquired Immune
Deficiency Syndrome.
127of neurologic disturbances (4.5%). Clinical monitoring (78.6%), ECG
monitoring (74.5%) and avoiding the combination (76.9%) were the
most frequent monitoring strategies to reduce the risk of DDI-
related ADEs.3.5. crpDDI duration & pDDIs at discharge
Themedian duration of a crpDDI was 1.2 days (IQR: 1.9; Q1: 0.9; Q3:
2.8). At ICU discharge, 44,366 admissions (42.7%) had at least one pDDI.
Table 2 shows the top 15 pDDIs at discharge. Interactions with
QT-prolonging agents occurred most frequently, followed by pDDIs po-
tentially leading to blood pressure disturbances (pDDI #3, #6, #8, #13),
potassium disturbances (pDDI #4, #10, #15) or glucose disturbances
(pDDI #2, #7).4. Discussion
Our study shows the mean number of pDDIs per 1000 medication
administrations was 70.1, dropping to 31.0 when considering only
crpDDIs. In total, 53.8% of the ICU patients was exposed to a pDDI and
38.2% to a crpDDI. On average patients were exposed to 2 pDDIs, of
which one clinically relevant. crpDDIs mostly occurred on the first ad-
mission day and lasted approximately one day. The most frequent
crpDDIs were interactions with QT-prolonging agents, digoxin, and
NSAIDs, increasing the potential risk of cardiac arrhythmia and bleed-
ing. Accordingly, ECGmonitoring, clinicalmonitoring and adding gastric
protection are commonly advised monitoring strategies. Around 42% of
the patients is dischargedwith a pDDI, of which themajority potentially
leads to disturbances in blood pressure, potassium or glucose.
Other studies report one to five pDDIs per admission, and overall
58.0% of ICU patients have a pDDI [1]. Consistently, we found on average
2 pDDIs per admission and 53.8% of all patients having a pDDI. Regard-
ing crpDDIs, we found on average 1.0 crpDDIs per admission and 38.2%
of the patients have a crpDDI. We identified one study similar to ours,
using a Delphi procedure to establish crpDDIs in the ICU [13]. This
single-center study by Askari et al. identified on average 1.7 crpDDIs
per admission, slightly higher compared to our findings. Differences in
clinical relevance definition and detection methods may explain this.
Another possible explanation may be the longer median LOS in their
study population (1.7 days vs 1.0 days). The high percentage of elective
surgery admissions may explain the relatively short LOS in our study
population.
Fig. 2. a Number and percentage of clinically relevant potential drug-drug interactions per admission. b Number of clinically relevant potential drug-drug interactions per admission for
each admission day.
Table 2
Top 15 most frequently occurring clinically relevant potential drug-drug interactions and top 15 most frequent potential drug-drug interactions at discharge.
Top 15 most frequent clinically relevant potential drug-drug interactions
crpDDI Number of crpDDIs (%)a Admissions with crpDDI (%)b
1 QT-PROLONGING AGENTSc + QT-PROLONGING AGENTSc 77,883 (72.2) 29,323 (28.2)
2 NSAIDs + CORTICOSTEROIDS 18,132 (16.8) 14,206 (13.7)
3 DIGOXIN + AMIODARON 1945 (1.8) 1512 (1.5)
4 NSAIDs + SEROTONERGIC AGENTS 1198 (1.1) 1066 (1.0)
5 DIGOXIN + ERYTHROMYCIN/CLARITHROMYCIN/ROXITHROMYCIN/AZITHROMYCIN 803 (0.7) 716 (0.7)
6 SALICYLIC ACID IN ANTITHRMBOTIC DOSE (UP TO 100 MG) + NSAIDs 719 (0.7) 686 (0.7)
7 HALOPERIDOL + INDUCERS 666 (0.6) 525 (0.5)
8 BETA-LACTAM ANTIBACTERIALS + TETRACYCLINES 561 (0.5) 456 (0.4)
9 THYROID HORMONES + ANTACIDS/CALCIUM PREPARATIONS 512 (0.5) 467 (0.4)
10 PHENYTOIN + VARIOUS INHIBITORS 439 (0.4) 390 (0.4)
11 THEOPHYLLINE + CYP1A2-INHIBITORS 436 (0.4) 413 (0.4)
12 PHENYTOIN + VALPROIC ACID 430 (0.4) 357 (0.3)
13 TACROLIMUS + CYP3A4-INHIBITORS 401 (0.4) 303 (0.3)
14 THEOPHYLLINE + ERYTHROMYCIN 321 (0.3) 286 (0.3)
15 DOPAMINERGIC AGENTS + ANTIPSYCHOTICS 207 (0.2) 157 (0.2)
Top 15 most frequent potential drug-drug interactions at intensive care unit discharge
pDDI Number of pDDIs
(%)d
Number of admissions with this pDDI at discharge
(%)b
1 QT-PROLONGING AGENTSc + QT-PROLONGING AGENTSc 18,635 (20.2) 13,548 (13.0)
2 BETA BLOCKING AGENTS (SELECTIVE) + INSULINS 11,960 (13.0) 11,227 (10.8)
3 RAAS-INHIBITORS + DIURETICS 8914 (9.7) 8206 (7.9)
4 RAAS-INHIBITORS + POTSASSIUM-SPARING AGENTS 8654 (9.4) 6861 (6.6)
5 NSAIDs + CORTICOSTEROIDS 8569 (9.3) 7928 (7.6)
6 BETA BLOCKING AGENTS (NON-SELECTIVE) + BETA AGONISTS 4727 (5.1) 4610 (4.4)
7 BETA BLOCKING AGENTS (NON-SELECTIVE) + INSULINS 4017 (4.4) 3930 (3.8)
8 BETA BLOCKING AGENTS + NSAIDs 2594 (2.8) 2500 (2.4)
9 CLOPIDOGREL + OMEPRAZOLE/ESOMEPRAZOLE 2036 (2.2) 2034 (2.0)
10 POTASSIUM + POTASSIUM SPARING AGENTS 1591 (1.7) 1300 (1.3)
11 SIMVASTATIN/ATORVASTATIN + CYP3A4-INHIBITORS 1504 (1.6) 1386 (1.3)
12 MIDAZOLAM/ALPRAZOLAM + CYP3A4-INHIBITORS 1411 (1.5) 1309 (1.3)
13 ALPHA BLOCKING AGENTS (NON-SELECTIVE) + BETA BLOCKING AGENTS/CALCIUM CHANNEL
BLOCKERS
1296 (1.4) 737 (0.7)
14 VITAMIN K ANTAGONISTS + ANTIBIOTICSe 1215 (1.3) 834 (0.8)
15 ACETAZOLAMIDE + DIURETICS (EXCL. POTASSIUM SPARING AGENTS) 1177 (1.3) 1040 (1.0)
NSAIDs = nonsteroidal anti-inflammatory drugs; RAAS = renin-angiotensin-aldosterone system; (cr)pDDI = (clinicaly relevant) potential drug-drug interaction.
a % of all clinically relevant potential drug-drug interactions.
b % of admissions with this (clinically relevant) potential drug-drug interaction.
c QT-prolonging agents with high risk for torsade de pointes.
d % of all potential drug-drug interactions at ICU discharge.
e Excluding sulfamethoxazole and trimethoprim/metronidazole/cefamandole.
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Table 3
Frequency of clinically relevant potential drug-drug interaction categorized by type of
increased potential risk and monitoring strategy.
Increased potential risk Number and percentage (%)a
Increased potential risk of side effects/toxicity 104,202 (96.6%)
Cardiac arrhythmias (including QT prolongation) 81,870 (75.9%)
Bleeding risk (including gastrointestinal ulcer
risk)
20,128 (18.7%)
Neurologic disturbances 4802 (4.5%)
Nephrotoxicity 754 (0.7%)
Other 206 (0.2%)
Hypotension or hypertension 112 (0.1%)
Myopathy 152 (0.1%)
Hematologic disturbances 74 (0.07%)
Serotonergic syndrome 0 (0%)
Masking hypoglycemia 0 (0%)
Electrolyte disturbance 0 (0%)
Potential risk of decreased efficacy 3706 (3.4%)
Antipsychotics (incl. haloperidol) 965 (0.9%)









Lipid-modifying agents 0 (0%)
Monitoring strategy Number and percentage
(%)a
Clinical monitoring 84,768 (78.6%)
Avoid combination 82,987 (76.9%)
ECG monitoring 80,400 (74.5%)
Risk-modifying strategy 21,053 (19.5%)
Add gastric protection (proton pump inhibitor) 20,074 (18.6%)
Separate moments of oral administration 922 (0.9%)
Other 57 (0.05%)
Potassium or potassium-sparing diuretic 0 (0%)
Monitoring of laboratory values 5107 (4.7%)
Drugs (therapeutic drug monitoring) 4874 (4.5%)
Kidney_function (serum creatinine) 284 (0.3%)
Liver function 154 (0.1%)







Adjust/titrate dose slowly 2513 (2.3%)
Other 492 (0.5%)
Blood pressure monitoring 101 (0.09%)
100% since clinically relevant potential drug-drug interactions may fall in multiple
categories.
ECG= electrocardiogram.
a Numbers may not add up to 107,908 and percentages may not add up to.
T. Bakker, A. Abu-Hanna, D.A. Dongelmans et al. Journal of Critical Care 62 (2021) 124–130Our study shows that by considering clinical relevance for the ICU
setting, the frequency of pDDIs drops by 47%. Despite the decrease,
risks for ICU patients remain substantial. Adjusted for clinical relevance,
ICU patients are still frequently exposed to increased risks of ADEs such
as QT-prolongation, bleeding and neurological disturbances. Although
research on DDI-related ADEs in the ICU is limited, QT-prolongation,
bleeding and neurological disturbances are mentioned as DDI-related
ADEs [14-17]. Edrees et al. [15] investigated overridden pDDI alerts
and associated ADEs. Seven of 78 ICU patients with an inappropriately
overridden severe alert experienced a QT-prolongation ADE. Armahizer
et al. [14] investigatedDDI-related QT-prolongation in ICU patientswith
aQTc ≥ 500ms. They found that 187 (37%) ICUpatients experiencedQT-
prolongation, with a DDI being the probable cause in 30 patients. Pa-
tients with QT-prolongation have a highermortality rate and prolonged
ICU stay [18]. Increasing awareness of pDDI risks could focus on
crpDDIs. Our results provide clues on how to improve DDI intervention
strategies such as CDSSs.1294.1. Tailoring CDSSs to the ICU
Warning prescribers only for crpDDIs could decrease alert fatigue,
reducing the risk of overriding relevant alerts and eventually improve
medication safety [19]. Considering crpDDI duration could further de-
crease alert fatigue, since most crpDDIs lasted 1 day [20]. For many
crpDDIs, this is too short to exert pharmacokinetic/pharmacodynamic
actions and cause harmful effects. Furthermore, initiating monitoring
actions directly from within the alert could help mitigate crpDDI risks
[21]. Moreover, for frequent crpDDIs such as NSAIDs + corticosteroids,
alerts could only be triggered when specific risk factors are present.
Also, as 42.7% of the patients are discharged with a pDDI, alerts could
be triggered upon ICU discharge to help physicians on non-ICU wards
to take appropriate monitoring actions. Lastly, most crpDDIs were re-
lated to QT-prolonging agents. This may be explained by the wide vari-
ation of often prescribed medications causing this crpDDI, including
cardiovascular medication, psychomodulating medication, antibiotics
and antiemetics. Not prescribingQT-prolonging agents often is impossi-
ble, but ICU patients routinely undergo ECG monitoring. ECG monitor-
ing for QT-prolongation, however, could be further personalized by
considering risk factors for QT-prolongation and potential arrhythmias
including older age, female gender, heart disease history, electrolyte ab-
normalities, and factors influencing the drug concentration, such as in-
fusion rate and impaired kidney function. This contextual information
could be considered by a CDSS, or presented within the DDI alert [22].
Additionally, many crpDDIs involved NSAIDs. Some ICUs refrain
from prescribing NSAIDs at all, preventing these crpDDIs. Instead
of following the sequence of the WHO pain treatment steps [23]
they skip the NSAIDs and prescribe opioids. CDSSs providing safer
treatment options effectively reduce prescription of potentially in-
appropriate medications [24].
This study has several strengths. First, to our knowledge this is the
first multicenter study on the frequency of (cr)pDDIs in the ICU. Our
study sample represents several ICU types and a large, heterogeneous
ICU patient population. Second, our clinical relevance definition was
based on a Delphi procedure where clinical relevance for the ICU was
assessed by amultidisciplinary expert panel. Third, we usedmedication
administrations instead of prescriptions to detect pDDIs, ensuring pa-
tients received the medication. This study also has some limitations.
First, we used only one database (G-standard) to identify pDDIs and
possibly missed pDDIs not included in this database [17]. However,
commonly prescribed medication in the ICU does not differ from other
countries. The top 10 medications implicated in pDDIs by Fitzmaurice
et al. [1] compares to our results. Second, since the G-standard is not tai-
lored to the ICU setting, the monitoring strategies not always apply to
the ICU, e.g. monitoring Hb is not included in the G-standard, while
ICUs use this strategy to monitor the risk of bleeding. Third, our detec-
tion algorithm did not consider the half-life of medications. Instead,
pDDIs were defined as the administration of two interacting medica-
tions within a 24 h period. This might lead to an overestimation of
pDDIs involving medications with a short half-life and an underestima-
tion of pDDIs involving medications with a long half-life. However, to
our knowledge no other pDDI study considered half-life, therefore our
results are comparable to other studies [1]. Fourth, measuring crpDDI
frequency does not gauge how much patient harm is caused.5. Conclusions
In linewith other studies, we showed that pDDIs frequently occur in
ICU patients. Our study shows the importance of considering clinical rel-
evance of pDDIs, as only 47.2% of the detected pDDIs are clinically rele-
vant in the ICU setting. The most frequent risks related to crpDDIs are
cardiac arrhythmia and bleeding. Aside from clinical relevance, pDDI
duration and timing, as well as contextual information, are important
to consider when tailoring CDSSs to the ICU setting. To further optimize
T. Bakker, A. Abu-Hanna, D.A. Dongelmans et al. Journal of Critical Care 62 (2021) 124–130prevention strategies, future studies should assess actual harm resulting
from pDDIs.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jcrc.2020.11.020.
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